Skip to content
Riskpilot
← Tilbage til søgning
Log ind
Få fuld adgang
Blueleven Pharma i Halmstad AB
AB
Active
Org 5591256564
Särdalsvägen 7, 305 71
Haverdal
Business and other management consultancy activities
· NACE 7020
Est. 2017
1-4 employees
Watchlist
Share
Sweden
/
Companies
/
Business and other management consultancy activities
/
Blueleven Pharma i Halmstad AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2021
1M
2022
1M
2023
1M
2024
1M
2025
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2021
1M
2022
1M
2023
1M
2024
1M
2025
Income statement
SEK thousands
Item
2021
2022
2023
2024
2025
Revenue
289
859
977
921
960
Staff expenses
—
−4
−65
−35
−115
EBITDA
172
803
725
772
546
Depreciation & amort.
−0
—
—
—
—
EBIT
172
803
725
772
546
Net financials
—
—
4
10
13
Profit before tax
135
603
549
583
433
Tax
−28
−124
−114
−123
−93
Net profit
107
478
435
460
340
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
2025
Total assets
400
1 003
1 503
1 647
1 782
Equity
245
533
778
848
939
Long-term debt
0
—
—
—
—
Short-term debt
95
210
285
160
78
Total debt
95
210
285
160
78
Financial ratios
5-year trend
EBITDA-margin
56.9%
This company
15.8%
Market median
+260% vs market
2021
2025
Soliditetsgrad
52.7%
This company
38.2%
Market median
+38% vs market
2021
2025
Egenkapitalforrentning
36.3%
This company
18.4%
Market median
+97% vs market
2021
2025
Nettoresultatgrad
35.5%
This company
8.1%
Market median
+338% vs market
2021
2025
Aktivomsætning
0.54×
This company
1.12×
Market median
-52% vs market
2021
2025
Gæld/egenkapital
0.90×
This company
0.62×
Market median
+45% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
More on Blueleven Pharma i Halmstad AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
